Literature DB >> 32275930

BAG5 promotes invasion of papillary thyroid cancer cells via upregulation of fibronectin 1 at the translational level.

Da-Lin Zhang1, Jia-Mei Wang2, Tong Wu3, Xin Du3, Jing Yan4, Zhen-Xian Du3, Hua-Qin Wang5.   

Abstract

Papillary thyroid cancer (PTC), the most common thyroid malignancy, has a strong propensity for neck lymph node metastasis, which will increase the risk of local recurrence and decrease the survival in some high-risk groups. Hence, it is essential to set up a reliable biomarker to predict lymph node metastasis. BAG5 is a unique member of the BAG cochaperone family because it consists of more than one BAG domain, which acts as modulator of chaperone activity. In this study, we found that expression of BAG5 was significantly increased in PTC cells and tissues. Neither overexpression nor downregulation of BAG5 altered the proliferation of PTC cells. On the contrary, overexpression of BAG5 significantly promoted, while knockdown of BAG5 significantly decreased migration and invasion of PTC cells. Along with this, fibronectin 1 (FN1) was significantly increased and decreased in cells that overexpress or downregulate BAG5, respectively. Mechanistically, we found that BAG5 modulated FN1 expression at the translational level and promoted invasion via suppression of miR-144-3p, which targeted the 3' untranslational region (UTR) of FN1 transcript. This study suggests that BAG5 is an important regulator of migration and invasion in PTC cells and may represent a novel therapeutic target for intervening in PTC progression.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  BAG5; Fibronectin 1; Papillary thyroid cancer

Mesh:

Substances:

Year:  2020        PMID: 32275930     DOI: 10.1016/j.bbamcr.2020.118715

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  10 in total

Review 1.  The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges.

Authors:  Pavel V Belousov
Journal:  Biomedicines       Date:  2022-02-17

2.  Circulating Exosomal miR-144-3p from Crohn's Disease Patients Inhibits Human Umbilical Vein Endothelial Cell Function by Targeting FN1.

Authors:  Peng Qu; Xiaoran Xie; Jingshu Chi; Xiaoming Liu; Peng Liu; Ju Luo; Huan Li; Sha Cheng; Xiujuan Xia; Xiong Chen; Canxia Xu
Journal:  Dis Markers       Date:  2022-06-02       Impact factor: 3.464

3.  Apoptosis-related genes-based prognostic signature for osteosarcoma.

Authors:  Fei Yang; Yi Zhang
Journal:  Aging (Albany NY)       Date:  2022-05-03       Impact factor: 5.955

Review 4.  BAG family proteins contributes to autophagy-mediated multidrug resistance of tumor.

Authors:  Jufang Guo; Xuelian Du; Chaolin Li
Journal:  Clin Transl Oncol       Date:  2022-03-12       Impact factor: 3.340

5.  Circ_0008305-mediated miR-660/BAG5 axis contributes to hepatocellular carcinoma tumorigenesis.

Authors:  Fuguo Yan; Bin Fan; Jianchu Wang; Wang Wei; Qianli Tang; Libai Lu; Zongjiang Luo; Jian Pu; Shan-Shan Yang
Journal:  Cancer Med       Date:  2021-01-22       Impact factor: 4.452

6.  Screening and bioinformatical analysis of differentially expressed genes in nasopharyngeal carcinoma.

Authors:  Weiqian Guo; Xiaomin Zheng; Lei Hua; Xianbin Zheng; Yangyang Zhang; Bin Sun; Zhenchao Tao; Jin Gao
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

7.  Over-Expression and Prognostic Significance of FN1, Correlating With Immune Infiltrates in Thyroid Cancer.

Authors:  Qi-Shun Geng; Tao Huang; Li-Feng Li; Zhi-Bo Shen; Wen-Hua Xue; Jie Zhao
Journal:  Front Med (Lausanne)       Date:  2022-01-24

Review 8.  MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Authors:  Maria Papaioannou; Angeliki G Chorti; Anthoula Chatzikyriakidou; Kleanthis Giannoulis; Sohail Bakkar; Theodosios S Papavramidis
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

Review 9.  Gene Editing with CRISPR/Cas Methodology and Thyroid Cancer: Where Are We?

Authors:  Cesar Seigi Fuziwara; Diego Claro de Mello; Edna Teruko Kimura
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

Review 10.  Protein Quality Control in Glioblastoma: A Review of the Current Literature with New Perspectives on Therapeutic Targets.

Authors:  Angela Rocchi; Hassen S Wollebo; Kamel Khalili
Journal:  Int J Mol Sci       Date:  2022-08-27       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.